Antifungal therapy: potential interactions with other classes of drugs.
Combination drug therapy is widely used for the management of many common medical conditions. The concurrent use of more than one drug can significantly alter the therapeutic and side-effect profile of each individual agent. Such drug-drug interactions are generally classified either as pharmacokinetic or pharmacodynamic. Oral agents used for the management of superficial fungal infections can have both types of interactions. This article describes common drug-drug interactions observed with amphotericin B, flucytosine, griseofulvin, ketoconazole, fluconazole, and itraconazole.
Bickers
D R
DR
Skin Diseases Research Center, Case Western Reserve University School of Medicine.
D000666:Amphotericin B / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D000935:Antifungal Agents / Q000145:classification / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D004347:Drug Interactions; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D005437:Flucytosine / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006118:Griseofulvin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D017964:Itraconazole / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D007654:Ketoconazole / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy* / Q000378:metabolism
D000935:Antifungal Agents; D017964:Itraconazole; D006118:Griseofulvin; D000666:Amphotericin B; D015725:Fluconazole; D005437:Flucytosine; D007654:Ketoconazole